Want to see TVTX full AI Analyst Report?
TVTX Stock Chart & Stats
$57.36
$0.68(1.20%)
At close: 4:00 PM EDT
$57.36
$0.68(1.20%)
Day’s Range― - ―
52-Week Range$15.03 - $60.10
Previous CloseN/A
Volume1.23M
Average Volume (3M)1.78M
Market Cap
$5.20B
Enterprise Value$2.79K
Total Cash (Recent Filing)$264.68M
Total Debt (Recent Filing)$327.66M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Aug 04, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding92,992,905
10 Day Avg. Volume1,112,147
30 Day Avg. Volume1,781,826
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)29.69
Price to Sales (P/S)6.95
P/FCF Ratio-167.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$59.25Price Target Upside3.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$680.20M
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone: FSGS ApprovalBeing the first and only FDA‑approved therapy for FSGS materially expands Travere's durable addressable market and clinical positioning. The approval opens >30,000 U.S. FSGS patients (and >100,000 total across IgA/FSGS), strengthening payer negotiations and long‑term uptake dynamics.
Strong Commercial Traction & Payer AccessSustained high prescription starts, steep YoY growth and established payer access (~97%) indicate robust commercial execution. These durable commercial capabilities support predictable revenue scaling, reduce launch friction for new indications, and improve the odds of converting eligible patients into long‑term users.
Pipeline Expansion Via Civorebrutinib LicenseThe exclusive license broadens Travere's kidney‑disease R&D footprint with a novel BTK asset, diversifying future revenue levers and indication coverage. This structural deal adds late‑stage development optionality and a strategic 10‑year non‑compete, supporting long‑term franchise building despite added obligations.
Bears Say
Elevated LeverageHigh debt relative to equity constrains financial flexibility and increases refinancing and interest risk over time. Even after recent refinancings, leverage limits capacity for opportunistic M&A, higher R&D spend without dilutive financing, and makes operating cash flow consistency critical for balance‑sheet stability.
Ongoing GAAP Losses And Rising Operating CostsMaterial increases in R&D and SG&A to support launches and trials raise the break‑even threshold. Continued GAAP losses mean profitability depends on sustained FILSPARI growth and successful pipeline outcomes; if revenue growth slows, elevated fixed costs could pressure margins and cash generation.
Pipeline Execution And Competitive RiskKey pipeline readouts (eg, HARMONY in 2027) and commercialization of new indications carry execution and regulatory risk. Simultaneous entrants in IgA nephropathy and uncertainties around clinical timelines could limit peak penetration and extend the time required to realize modeled revenues.
Travere Therapeutics News
TVTX FAQ
What was Travere Therapeutics, Inc.’s price range in the past 12 months?
Travere Therapeutics, Inc. lowest stock price was $15.03 and its highest was $60.10 in the past 12 months.
What is Travere Therapeutics, Inc.’s market cap?
Travere Therapeutics, Inc.’s market cap is $5.20B.
When is Travere Therapeutics, Inc.’s upcoming earnings report date?
Travere Therapeutics, Inc.’s upcoming earnings report date is Aug 04, 2026 which is tomorrow.
How were Travere Therapeutics, Inc.’s earnings last quarter?
Travere Therapeutics, Inc. released its earnings results on May 04, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.158.
Is Travere Therapeutics, Inc. overvalued?
According to Wall Street analysts Travere Therapeutics, Inc.’s price is currently Undervalued.
Does Travere Therapeutics, Inc. pay dividends?
Travere Therapeutics, Inc. does not currently pay dividends.
What is Travere Therapeutics, Inc.’s EPS estimate?
Travere Therapeutics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Travere Therapeutics, Inc. have?
Travere Therapeutics, Inc. has 92,992,905 shares outstanding.
What happened to Travere Therapeutics, Inc.’s price movement after its last earnings report?
Travere Therapeutics, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went down -0.245%.
Which hedge fund is a major shareholder of Travere Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.25 (3.29% Upside)
$59.25 (3.29% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
259.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.16%
Trailing 12-Months
Company Description
Travere Therapeutics, Inc.
Travere Therapeutics (TVTX) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on kidney-related conditions. The company’s core commercial product is FILSPARI (sparsentan), and it has also marketed Thiola/Thiola EC (tiopronin) for cystinuria.
TVTX Company Deck
TVTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and clinical momentum: a landmark FDA approval in FSGS, record demand and an 88% YoY increase in FILSPARI sales, encouraging pipeline progress (HARMONY restart with 2027 readout expectation), and improved non-GAAP profitability. Offsetting these positives are significant near-term cost increases (R&D and SG&A), higher royalty expense due to accounting changes, a continuing GAAP net loss, and some short-term revenue recognition/timing headwinds and education needs with physicians and payers. Overall, the positives (major approval, large sales growth, record demand, and clear runway to advance the pipeline) outweigh the near-term financial and operational challenges.View all TVTX earnings summariesTVTX Stock 12 Month Forecast
Average Price Target
$59.25
▲(3.29% Upside)
Technical Analysis
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
1.61% Insiders
39.17% Mutual Funds
3.58% Other Institutional Investors
39.93% Public Companies and
Individual Investors